Vancomycin pharmacokinetics in critically ill patients receiving continuous haemodiafiltration with a polyethyleneimine‐coated polyacrylonitrile membrane
Autor: | Takuya Yamashina, Yosei Kawamata, Hiroko Tsukada, Shinya Takashima, Yoichi Hiraki, Moeko Tsuruyama, Masahisa Nagano, Airi Fujimoto, Minako Tsuruta |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
Continuous haemodiafiltration Critical Illness Acrylic Resins Hemodiafiltration 030226 pharmacology & pharmacy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Elimination rate constant Pharmacokinetics Vancomycin medicine Humans Polyethyleneimine Tissue Distribution Pharmacology (medical) Trough Concentration 030212 general & internal medicine Aged Retrospective Studies Aged 80 and over Pharmacology Volume of distribution Chromatography Chemistry Polyacrylonitrile Membranes Artificial Anti-Bacterial Agents Membrane Female Half-Life medicine.drug |
Zdroj: | Journal of Clinical Pharmacy and Therapeutics. 45:1143-1148 |
ISSN: | 1365-2710 0269-4727 |
Popis: | What is known and objective We investigated the elimination efficiency and pharmacokinetics (PK) parameters of vancomycin (VCM) in patients undergoing continuous haemodiafiltration (CHDF) using a polyethyleneimine-coated polyacrylonitrile membrane (AN69ST) for dosage adjustment. Methods We conducted a retrospective study of CHDF patients treated with VCM from December 2017 to August 2019. We calculated PK parameters of VCM and determined the 24-hour dose required to maintain the target trough concentration of VCM (VCM_trough ). Results and discussion The average (95% CI) volume of distribution and total clearance of VCM were 75.5 L (63.7-87.3 L) and 1.84 L/h (1.38-2.30 L/h), respectively, and the elimination rate constant and half-life were 0.026/h (0.017-0.034/h) and 31.2 h (22.8-39.5 h), respectively. The average AN69ST clearance of VCM (CL_CHDF ) was 0.69 L/h (0.52-0.86 L/h). The estimated average doses required to maintain VCM_trough of 10, 15 and 20 μg/mL were 623.1 mg (379.8-866.4 mg), 934.6 mg (569.7-1299.5 mg) and 1246.2 mg (759.6-1732.8 mg), respectively. What is new and conclusion The PK of VCM and CL_CHDF of AN69ST were clarified. These results suggest that it is possible to adjust the dose of VCM in using AN69ST, which efficiently removes cytokines, and contributes to improvement of serious infections. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |